← Eichor
Condition: Refractory Peripheral T Cell Lymphoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Refractory Peripheral T Cell Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
NA · 1 location(s) · Medical College of Wisconsin · NCT05794880SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma
Phase 3 · 1 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT06122389Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Phase 1 · 10 location(s) · SciTech Development, Inc. · NCT04234048A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Phase 1 · 17 location(s) · Arvinas Inc. · NCT06393738Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07372352Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06151106GVM±R in Patients With Relapsed or Refractory Aggressive NHL.
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06244368A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
Phase 1 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06914037Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Phase N/A · 5 location(s) · Children's Hospital Medical Center, Cincinnati · NCT06131801Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL
Phase 2 · 6 location(s) · University of Virginia · NCT04747236A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL
Phase 1/Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06855823A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in
Phase 1 · 2 location(s) · Mayo Clinic · NCT03017820A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Perip
Phase 3 · 1 location(s) · Evopoint Biosciences Inc. · NCT06776952Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a Ne
Phase 1/Phase 2 · 8 location(s) · Instituto de Investigación Biomédica de Salamanca · NCT06378190Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
Phase 2 · 1 location(s) · University of Michigan Rogel Cancer Center · NCT05956041An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal A
EARLY_Phase 1 · 1 location(s) · Second Affiliated Hospital of Soochow University · NCT07598578Q702 for the Treatment of Patients With Hematologic Malignancies
Phase 1 · 2 location(s) · Mayo Clinic · NCT06712810Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
Phase 1 · 1 location(s) · Stephan Grupp MD PhD · NCT06934382Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
Phase 1 · 2 location(s) · Baylor College of Medicine · NCT06176690CD7 CAR-T Cells in T-cell Lymphoma/Leukemia
NA · 1 location(s) · Shenzhen University General Hospital · NCT05620680CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
Phase 2 · 2 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT04083495Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL
Phase 2 · 1 location(s) · The Affiliated Hospital of Xuzhou Medical University · NCT07058103Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523555Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Phase 2 · 6 location(s) · Great Novel Therapeutics Biotech & Medicals Corporation · NCT05833724CD4CAR for CD4+ Leukemia and Lymphoma
Phase 1 · 6 location(s) · Huda Salman · NCT03829540Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT05182957Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma
Phase 1/Phase 2 · 1 location(s) · Rong Tao · NCT07502768Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory
Phase 1/Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07093710Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
Phase 1 · 2 location(s) · Baylor College of Medicine · NCT04288726
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.